Chemo Therapy

Clinical Benefit of Docetaxel or Enzalutamide After Progression on First-Line Abiraterone and Prednisone in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC) *

Abiraterone acetate (AA) or Zytiga has demonstrated a survival benefit in the pre-chemotherapy setting for men with advanced prostate cancer that has become castrate resistant (mCRPC). As a result it is in widespread clinical use in the United States prior to the use of chemotherapy with docetaxel. Since its FDA approval post chemotherapy there has [...]

By Malecare|2017-10-19T10:48:05-04:00August 20th, 2014|abiraterone acetate, Advanced Prostate Cancer, Chemo Therapy, Cross Resistance, Drugs & Treatments, enzalutamide, Uncategorized, Understanding APC, Xtandi|0 Comments

Complementary and Alternative Medicine with Chemotherapy

The following was written and posted by Paul Edwards to the Advanced Prostate Cancer Online Support Group: The March 2014 issue of the Asia-Pacific Journal of Clinical Oncology published an article “Why do some cancer patients receiving chemotherapy choose to take complementary and alternative medicines and what are the risks?” by authors from University of Queensland [...]

By Malecare|2017-10-19T10:48:06-04:00August 6th, 2014|Advanced Prostate Cancer, Chemo Therapy, Drugs & Treatments, supplements, Uncategorized|0 Comments

Can Chemotherapy (Docetaxel) Be Enhanced By Zoledronic Acid Pretreatment in Resistant Prostate Cancer Cells *

Docetaxel is the only globally approved first-line chemotherapy for the treatment of castrate resistant prostate cancer. Yhe universal truth is that all men taking docetaxel will become refractory to the treatment. Zoledronic acid (ZA) is the most commonly used member of nitrogen-containing bisphosphonate family. By itself it has anti-tumor activity, including in prostate cancer. In [...]

By Malecare|2014-08-05T14:08:36-04:00August 5th, 2014|Advanced Prostate Cancer, ASCO, bisphosphonates, Chemo Therapy, Chemo Therapy Failure, Combination Therapy, Drugs & Treatments, Research, Uncategorized, Understanding APC, Zometa|0 Comments

What are the Clinical implications of Chemotherapy for Men with Advanced Prostate Cancer Under the Age of 60 years?

Yesterday’s post was about the use of chemotherapy (with docetaxel) for the treatment of men with advanced prostate cancer who were 80 years old or older. Today’s post is about the use of chemotherapy in men 60 years or younger. The research for both of these posts was performed by the same team of scientists [...]

By Malecare|2017-10-19T10:48:07-04:00July 22nd, 2014|Advanced Prostate Cancer, Chemo Therapy, Drugs & Treatments, Research, survival, Uncategorized, Understanding APC|0 Comments

Should Men Over the Age of 80 Years Consider Chemotherapy? *

Chemotherapy (chemo with docetaxel) has a reputation for being a difficult therapy loaded with many side effects. I believe that this reputation is overblown given that all of our new non-chemotherapies (other than Provenge) come with their own list of significant side effects. However, its reputation is in the minds of many, so men who [...]

By Malecare|2017-10-19T10:48:07-04:00July 21st, 2014|Advanced Prostate Cancer, Chemo Therapy, Drugs & Treatments, Research, Uncategorized, Understanding APC|1 Comment

Anticoagulants May Increase Survival in Men with Advanced Prostate Cancer Taking Chemotherapy*

Over the past two to three years there have been some small studies that have indicated that the use of concomitant anticoagulants along with docetaxel (chemotherapy) may improve overall survival The most recent examination of this issue was performed by a team led by Emmanuel S. Antonarakis, MD, of Johns Hopkins University in Baltimore. They [...]

By Malecare|2020-02-04T11:48:55-05:00July 11th, 2014|Advanced Prostate Cancer, Chemo Therapy, Drugs & Treatments, General Information, Research, survival, Uncategorized, Understanding APC|0 Comments

Enhancement of Chemotherapy by Pretreating Cells with Zoledronic Acid (Zometa)*

Chemotherapy using docetaxel remains an important therapy, despite the newly approved drugs, to treat hormone refractory prostate cancer. Chemotherapy improves survival, however, all men taking it will eventually become refractory to the treatment. Zoledronic acid (ZA) is the most potent member of nitrogen-containing bisphosphonate family and has anti-tumor activity in prostate cancer. In a study, [...]

By Malecare|2014-07-02T09:34:28-04:00July 2nd, 2014|Advanced Prostate Cancer, bisphosphonates, Chemo Therapy, Chemo Therapy Failure, Drugs & Treatments, Research, Uncategorized, Zometa|0 Comments

Drunk by Chemotherapy!

Want your insurance company to pay for next drunk? According to the FDA they in fact might be willing! All kidding aside, the FDA has issued a drug safety communication regarding the risk of intoxication with some of the intravenous generic prostate cancer chemotherapy (docetaxel) formulations containing ethanol. The drugs are marketed as generic docetaxel [...]

By Malecare|2021-02-17T11:03:15-05:00June 24th, 2014|Advanced Prostate Cancer, Chemo Therapy, Drugs & Treatments, Uncategorized, Understanding APC|0 Comments

An Analysis of the Clinical Benefit of Chemotherapy & Xtandi Post Zytiga in Men with Metastatic Castration Resistant Prostate Cancer

The FDA approved Abiraterone acetate (Zytiga) plus prednisone because it demonstrated a survival benefit for men with metastatic castrate resistant prostate cancer (mCRPC) in the pre-chemotherapy setting. Given the newness of the approval of Zytiga in this disease stage there is a lack of data on how Zytiga affects the efficacy of enzalutamide (Xtandi) or [...]

By Malecare|2017-10-19T10:48:08-04:00June 23rd, 2014|abiraterone acetate, Advanced Prostate Cancer, Chemo Therapy, Cross Resistance, Drugs & Treatments, enzalutamide, Research, Uncategorized, Understanding APC, Xtandi, Zytiga|1 Comment

Finding BioMarkers to Drug Sensitivity, The Next Step – ASCO Annual Meeting at ASCO GU

Now that we have new treatments available to fight advanced, metastatic prostate cancer we need ways to decide on the best treatments given that many of the treatments occupy the same disease space. This is especially important with the soaring costs of many treatments as well as the need to not waste time by giving [...]

By Malecare|2017-10-19T10:48:09-04:00June 17th, 2014|Advanced Prostate Cancer, biomarkers, Chemo Therapy, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Drugs & Treatments, enzalutamide, prognostic tools, Uncategorized, Understanding APC, Xtandi|0 Comments